Terremoto Biosciences
Stub active Updated Apr 15, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
About
Terremoto Biosciences is a biotechnology company leveraging lysine-based covalency to develop selective AKT1-inhibitor medicines for oncology and hereditary hemorrhagic telangiectasia 1. The company plans to initiate Phase 1 clinical trials for its lead candidates in the coming months 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-15 | Series C | $108M | RA Capital Management | Deep Track Capital, Osage University Partners, BeOne Medicines, OrbiMed, Third Rock Ventures, Novo Holdings, Cormorant Asset Management 1 |
What Investors Say
No verified investor quotes available at this time.
What Founders Say
No verified founder quotes available at this time.
Sources
-
Bakersfield.com / AP, “Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia,” April 15, 2026. https://www.bakersfield.com/ap/news/terremoto-biosciences-closes-108-million-series-c-financing-to-advance-selective-akt1-inhibitors-in-oncology/article_fd13c751-4da0-5363-a15b-147a534b48dd.html↩↩↩